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ARTICLE

Emergence and Control of Fluoroquinolone-Resistant,
Toxin A-Negative, Toxin B-Positive Clostridium difficile
Denise Drudy, PhD; Norma Harnedy, MB, MRCPI; Seamus Fanning, PhD;
Margaret Hannan, MD, MRCPI, MRCPath; Lorraine Kyne, MD, FRCPI, MPH

BACKGROUND. Clostridium difficile is a major cause of infectious diarrhea in hospitalized patients. Between August 2003 and January
2004, we experienced an increase in the incidence of C. difficile-associated disease. We describe the investigation into and management of
the outbreak in this article.
METHODS. A total of 73 consecutive patients with nosocomial C. difficile-associated diarrhea were identified. C. difficile isolates were
characterized using toxin-specific enzyme immunoassays, a tissue-culture fibroblast cytotoxicity assay, polymerase chain reaction (PCR),
and antimicrobial susceptibility tests. Rates of recurrence and of C. difficile colitis were recorded. Changes in antibiotic use and infection
control policies were documented.
RESULTS. The incidence of C. difficile-associated diarrhea peaked at 21 cases per 1,000 patient admissions. Of the C. difficile isolates
recovered, 85 (95%) were identical toxin A-negative and toxin B-positive strains, corresponding to toxinotype VIII and PCR ribotype 017.
All clonal isolates were resistant to multiple antibiotics, including ofloxacin, ciprofloxacin, levofloxacin, moxifloxacin, and gatifloxacin
(minimum inhibitory concentrations [MICs] of greater than 32 /tg/mL) and erythromycin, clarithromycin, and clindamycin (MICs of
greater than 256 /ng/mL). Recurrent C. rfi/^ci/e-associated disease occurred in 26 (36%) of the patients. At least 10 (14%) of the patients
developed C. difficile colitis. Additional infection control measures introduced included the use of ward memos, a hand-hygiene awareness
campaign, increased environmental cleaning, attention to prescribing practices for antibiotics, increased awareness of diarrheal illness, and
early isolation of affected patients. Total use of fluoroquinolones did not change throughout the study period. Despite persistence of this
toxin-variant strain, the incidence of C. difficile-associated disease in our institution decreased to fewer than 5 cases per 1,000 admissions.
CONCLUSIONS. We report on the emergence of a fluoroquinolone- and clindamycin-resistant, toxin A-negative, and toxin B-positive
strain of C. difficile associated with an outbreak of C. iij^ri/e-associated disease in our institution during a 6-month period. We found
that careful attention to improvement of infection control interventions was the most important means of controlling this nosocomial
pathogen.
Infect Control Hosp Epidemiol 2007; 28:932-940

Clostridium difficile is a common nosocomial pathogen and
a major cause of infectious diarrhea in hospitalized patients. 1
Patients who receive antibiotic therapy are particularly susceptible to colonization with C. difficile and subsequent C.
dijficile-associated disease (CDAD). 2 The risk of CDAD appears to be greater with certain antimicrobial agents.3"6 Recent
studies also suggest that the risk of CDAD increases if C.
difficile is resistant to the administered antimicrobial. 6 Resistance to clindamycin and third-generation cephalosporins has
been well documented; however, resistance to fluoroquinolones, in particular the newer generation
fluoroquinolones,
is a more recent development.6"8 Other worrisome trends in
the epidemiology and pathogenesis of CDAD include the
emergence of toxin-variant and hypervirulent toxin-produc-

ing strains; the latter have been associated with more-severe
3
disease and increased 30-day mortality.,3,9-11
There is ongoing surveillance of all patients with CDAD
in our institution (The Mater Misericordiae University Hospital; Dublin, Ireland). From 2001 to 2003, we experienced
winter peaks in the incidence of CDAD. From June 2001 to
May 2002, levofloxocin was the first-line antimicrobial agent
used for treatment of community-acquired pneumonia (CAP).
This regimen was switched to cefuroxime plus clarithromycin
in May 2002 because of concerns regarding the emergence
of fluoroquinolone resistance in Streptococcus pneumoniae
strains. However, the incidence of CDAD increased to 33 cases
per 1,000 patient admissions in January 2003, resulting in the
discontinuation of use of cefuroxime as a first-line agent for
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CAP. Since April 2003, ofloxacin and benzylpenidllin have
been the recommended first-line agents for CAP in our hospital. Despite a decrease in the incidence of CD AD in May
and June 2003, we became aware of an increase in the incidence of CDAD in July 2003, when rates increased to more
than 10 cases per 1,000 patient admissions. As part of an
investigation into this outbreak, we performed cultures, typed
strains, and performed antimicrobial-susceptibility testing on
all isolates recovered from patients with CDAD during this
period. We also documented rates of recurrence and of C.
difficile colitis.

ated diarrhea was defined as onset of C. difficile-associated
diarrhea at least 48 hours after admission in a patient with
no known previous history of CDAD. Recurrent CDAD was
defined as the development of a new episode of CDAD confirmed by a positive results of C. difficile toxin test of stool
during a 60-day follow-up period, after resolution of the episode that began at enrollment for at least 48 hours and after
discontinuation of therapy with metronidazole or vancomycin. Patients were classified as having C. difficile colitis on
the basis of radiological or endosopic findings.

METHODS

C. difficile isolates were cultured on cyloserine-cefoxitin-fructose agar. Ninety C. difficile isolates were recovered from 64
of 73 patients in this study and included a single isolate from
each patient with 1 episode of diarrhea and 1 isolate representing each recurrent episode of diarrhea. We were unable
to culture C. difficile from fecal specimens from 9 patients
who tested positive for C. difficile toxin, because these patients
had received metronidazole. However, these patients were still
regarded as having tested positive for C. difficile in the epidemiological evaluation.

Study Population and Specimens
The Mater Misericordiae University Hospital is a 570-bed,
university-affiliated hospital in Dublin, Ireland, that serves a
population of approximately 250,000, 11% of whom are aged
65 years or older. There are 37 wards that are arranged into
3-4 bays of 6 beds each. The average ratio of bathrooms to
patients is 1:6. There are 84 single rooms, 39 of which are
isolation rooms with anteroom and gowning facilities. Until
2000, there were 2 infection control nurses; this number increased to 4 in October 2002.
We prospectively studied all newly diagnosed cases of nosocomial CDAD between August 2003 and January 2004. Consecutive cases were identified by daily review of requests for
assay of stool samples for C. difficile toxin (C. difficile Tox A/
B II enzyme-linked immunosorbent assay; Techlab) at the
clinical microbiology laboratory. Patients with a prior history
of CDAD at our institution or of CDAD that was not nosocomially acquired were excluded from the study. A total of
73 patients received a diagnosis of newly acquired nosocomial
CDAD in this period. Patients were monitored until hospital
discharge or death. For each patient, we recorded age, sex,
Charlson comorbidity index,12 ward of admission, ward transfers, antimicrobial agents received before onset of CDAD, all
medications received, type of feeding regimen (oral feeding,
tube feeding [by nasogastric, percutaneous gastrostomy, or
jejunostomy tube], or total parenteral nutrition), serum albumin levels, and white blood cell (WBC) count, and body
temperature at the time of diagnosis of CDAD. Radiological
or endoscopic investigations and specific anti-C. difficile therapies were recorded. The clinical management after the onset
of C. dij^ci/e-associated diarrhea was also documented. All
additional infection control interventions and overall use of
quinolone and cephalosporin antibiotics were recorded.

Culture of Isolates

Testing for C. difficile Toxins
Toxin-specific immunoassays and cytotoxicity assays were
used to detect toxin production after culture of C. difficile in
brain-heart infusion broth for 72 hours. Toxins A and B were
detected using the C. difficile Tox A/B II test (Techlab) and
a tissue-culture cytotoxin assay (IMR-90; European Collection of Cell Cultures), respectively.
Molecular Analysis of Isolates
Genomic DNA was extracted from broth cultures of C. difficile
and was quantified using the PicoGreen dsDNA Quantitation
Kit (Molecular Probes). Polymerase chain reaction (PCR) restriction-fragment-length polymorphism (RFLP) "toxinotyping" was used to investigate all 90 C. difficile isolates.13,14 PCR
ribotyping was performed in accordance with Stubbs et al.,15
with some minor modifications. DNA fingerprints were stored
as tagged-image-file-format (TIFF) files and were imported
into BioNumerics software, version 4.0 (Applied Maths), with
which dendrograms were created using the Dice coefficient
and the unweighted pair-group method with arithmetic mean
for cluster correlation.
Antibiotic Susceptibility Testing

Susceptibility to clindamycin, erythromycin, clarithromycin,
ofloxacin, ciprofloxacin, levofloxacin, gatifloxacin, and moxifloxacin was determined using the Etest (AB Biodisk). The
Diarrhea was defined as a change in bowel habit with 3 or
minimum inhibitory concentration (MIC) was defined as
more unformed bowel movements for at least 2 days. C.
dij^ci/e-associated diarrhea was defined as diarrhea not atthe lowest concentration of antibiotic that prevented vistributed to any other cause and associated with a stool test
ible growth after 48 hours under anaerobic conditions and
positive for C. difficile toxin. Nosocomial C. difficile-associ- was interpreted according to Clinical and Laboratory StanDefinitions
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TABLE i. Infection Control Interventions Used Before and During an Outbreak
of Clostridium difficile Infection, by Year
2002
Daily surveillance of patients with gastrointestinal symptoms
Purchase of new bedpans and commodes
Additional ward cleaning
Increase in the number of infection control personnel
Introduction of Spiragel alcohol-based hand rub
2003
Distribution of ward memos
Topic: hand hygiene
Topic: early recognition of symptoms
Topic: early isolation and cohorting on the basis of clinical symptoms
Increased awareness and improved reporting of infection
Lectures given at grand rounds and postgraduate lectures on infection control
Hand-hygiene awareness campaign
Enhanced environmental cleaning

dards Institute (CLSI) breakpoints for clindamycin and
trovofloxacin.
Statistical Analysis
Patients with severe CDAD and patients with nonsevere
CDAD were compared. We used the x 2 test or 2-tailed Fisher
exact test, for categorical variables, and the Student t test or
Wilcoxon rank-sum test, for continuous variables. We used
multivariable logistic regression analyses to determine the independent predictors of severe disease. Age and sex were
entered into each model, along with variables associated with
the outcomes in univariate analyses ( P < .1). Only variables
statistically significantly associated with the outcomes were
included in the final models. All analyses were performed
using the SAS software system, version 6.12 (SAS Institute).
The a level was set at 0.05. All P values were 2 sided.

RESULTS
Incidence of CDAD
From July 2003 through January 2004, there were 73 consecutive patients with CDAD and the corresponding C. difficile isolates analyzed. In September 2003, the incidence of
CDAD peaked at 21 cases per 1,000 patient admissions.
Heightened infection control measures were introduced and
are outlined in Table 1 and below. These measures included
recommendations that all antibiotic prescriptions should be
reviewed with regard to specific start and stop dates and the
necessity for antibiotic treatment. However, fluoroquinolone
use was not discouraged, and ofloxacin and benzylpenicillin
remained the first-line agents for treatment of CAP. By January 2004, incidence rates had returned to baseline levels and
have remained stable up to the time that the analysis was

FIGURE i. Annual time line showing the number of new patients with nosocomial Clostridium difficile-associated disease at Mater
Misericordiae University Hospital in 2003 (gray boxes), 2004 (open boxes), and 2005 (black boxes), by month.

FLUOROQUINOLONE-RESISTANT, TOXIN A-NEGATIVE, TOXIN B-POSITIVE C. DIFFICILE

935

TABLE 2. Demographic and Clinical Characteristics of Patients With Clostridium difficileAssociated Disease (CDAD) and Factors Associated With Severe Disease

Characteristic
Male sex
Age, years
Mean ± SD
Median (range)
Albumin level at admission, g/L
Mean ± SD
Median (range)
No. of antibiotics received before
diagnosis of CDAD
Mean ± SD
Median (range)
Use of H2-receptor antagonists
Use of proton-pump inhibitors
Intensive care unit
Enteral feeding*
Any
Nasogastric feeding
Charlson comorbidity index
Mean ±SD
Median (range)
No. of comorbidities
Mean ±SD
Median (range)

Patients with
severe disease
(« = 10)

Patients with
nonsevere disease
(n = 63)

All patients
{n = 73)

7 (70)

26 (41)

33 (45)

P
.09

70.6 ± 14.6
72.5 (38-88)

72.7 ± 12.9
73 (29-95)

72.4 ± 13.0
73 (29-95)

NS

29.9 ± 7.5
29.5 (15-39)

26.7 ± 6.5
28 (10-40)

27.1 ± 6.7
28 (10-40)

NS

1.6 ± 0.8
2 (0-3)
9(12)
44 (66)
19 (26)

NS
NS
NS
.06

36 (49)
34 (47)

.04
.02

1.6 ± 0.7
1.5 (1-3)
1(10)
5 (50)
5 (50)
8 (80)
8 (80)

1.6 ± 0.8
2 (0-3)
8(13)
39 (62)
14 (22)
28 (44)
26 (41)

1.6 ± 1.7
1.5 (0-5)

4.5 ± 2.2
4 (0-12)

4.1 ± 2.3
4 (0-12)

.0003

3.8 ± 1.9
6 (1-12)

6.1 ± 2.6
6 (1-12)

5.8 ± 2.6
6 (0-12)

.01

NOTE. Data are no. (%) of patients, unless otherwise indicated. NS, not significant.
" Feeding by nasogastric, percutaneous gastrostomy, or jejunostomy tube.

completed (fewer than 5 cases per 1,000 patient admissions).
Figure 1 shows all new cases of CDAD from 2003 through
2005.
Patient Characteristics and Outcomes
The 73 patients affected were predominantly older white patients (median age, 73 years; range, 29-95 years). Most had
clinically significant comorbid disease (median Charlson
comorbidity score, 4; range, 0-12). Nineteen (26%) of the
patients had severe underlying disease and spent some time
in the intensive care unit (ICU) or high-dependency unit.
Other baseline characteristics are shown in Table 2.
Recurrent CDAD
Of the 73 patients studied, 47 (64%) had a single episode of
CDAD, 26 (36%) had a single recurrent episode of CDAD,
and 7 (27%) had a second recurrence of CDAD during the
outbreak period. All patients with recurrent CDAD were given
treatment with antibiotics for 10 days. The frequency of recurrence based on the type of treatment received was not
examined.

C. difficile Colitis
At least 10 (14%) of the patients developed C. difficile colitis.
All these patients showed evidence of colitis on abdominal
computed tomography (CT) and had median WBC counts
of 18.8 x 109 cells/L (range, 10.2 x 109-67.2 x 109 cells/L).
One of these patients had a total colectomy for extensive
pseudomembranous colitis. He survived the initial illness but
subsequently died of unrelated causes. Of the other 9 patients
with colitis, 4 died within 30 days after the onset of symptoms.
Patients with severe disease were more likely to be male
(P = .09) and to have severe underlying disease that necessitated treatment in the ICU (P = .06) (Table 2). Although
patients with more-severe disease had significantly lower
scores on the Charlson comorbidity index (P = .0003), they
were significantly more likely to have received enteral feeding
(P = .04), in particular nasogastric feeding (P = .02), compared with patients with less severe disease. The unadjusted
odds ratio (OR) for severe disease associated with nasogastric
feeding was 5.69 (95% confidence interval [CI], 1.12-29.00);
however, in a multivariable logistic regression analysis, after
adjustment for age and ICU stay, the OR was 4.69 (95% CI,
0.81-28.62). No other independent predictors of severe dis-
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TABLE 3. Minimum Inhibitory Concentration (MIC) Values for Fluoroquinolone and Macrolide Antibiotics for 85 Toxin-Variant Clostridium difficile Isolates (TV) and 5 Nonvariant
Isolates (NV)
MIC, ;ug/mLa
Antibiotic,
by class
Fluoroquinolone
Ofloxacin
Ciprofloxacin
Levofloxacin
Moxifloxacin
Gatifloxacin
Macrolide
Clindamycin
Erythromycin
Clarithromycin

MIC 50

MIC 90

Median

Range

TV

NV

TV

NV

TV

NV

TV

NV

>32
>32
>32
>32
>32

>32
>32
2
0.25
0.25

>32
>32
>32
>32
>32

>32
>32
2
0.5
0.38

>32
>32
>32
>32
>32

>32
>32
1.5-2
0.125-0.5
0.25-0.38

>32
>32
>32
>32
>32

>32
>32
2
0.315
0.25

>256
>256
>256

4
1.5
0.5

>256
>256
>256

4
1.5
0.5

>256
>256
>256

4
1.5
0.5

>256
>256
>256

4
1.5
0.5

NOTE. The 85 toxin-variant C. difficile isolates were negative for toxin A and positive for toxin B. The
5 nonvariant isolates were positive for toxins A and B. MIC50, minimum inhibitory concentration required
to inhibit growth of 50% of organisms; MIC9(), minimum inhibitory concentration required to inhibit
growth of 90% of organisms.
* MICs that were beyond the detection limits of the test used are so indicated: >32 /xg/mL for fluoroquinolones and >256 fig/mL for macrolides.

ease were identified (Table 2). All patients with severe disease
were infected with a fluoroquinolone-resistant toxin-variant
C. difficile strain.
Clinical Management of CDAD
Whenever possible, use of antibiotics that predispose to
CDAD was discontinued; however, many patients had concurrent bacterial infections that necessitated continued use
of antibiotics. One patient with a single episode of CDAD
received supportive care only. The remaining 72 patients were
treated with metronidazole and/or vancomycin. Use of proton-pump inhibitors and H2-receptor antagonists was continued. Patients did not receive probiotics. Contact isolation
was implemented when possible. With the rare exception of
patients who could not be isolated, the ward was quarantined
and no patients were admitted or discharged from that ward
until they were symptom free for longer than 48 hours and
until laboratory results confirmed no evidence of CDAD. If
a case of CDAD was identified on a 6-bed unit, additional
cases were sought.
Trends in Antibiotic Use
Sixty-nine (95%) of the patients received 1 or more antimicrobial before the onset of CDAD (Table 3). Thirty (41%)
of the patients received treatment with a single antibiotic, and
30 patients (41%) received treatment with 2 antibiotics. Four
patients did not receive any antibiotics while in the hospital.
Of the patients with CDAD, 33 (27%) had received augmentin and ofloxacin, alone or in combination. Trends in
antibiotic prescribing since 2001 for individual fluoroquinolones and cephalosporins and for each class as a whole are

shown in Figure 2. Total cephalosporin use in 2002 (16,992
g) was almost twice that in 2001 (31,132 g). In contrast, total
use of cephalosporins from 2003 through 2005 showed a
downward trend, with 15,140 g used in 2003, 13,719 g used
in 2004, and 11,696 g used in 2005. Total use of fluoroquinolones in 2002 through 2005 was almost half that in 2001
(Figure 2).
Infection Control Interventions
A number of changes were introduced to the hospital's infection control policy in 2002, after the first case of norovirus
gastroenteritis was diagnosed in the hospital. These included
the following measures: (1) an audit of all sinks, soaps, and
moisturizers used throughout the hospital; (2) a switch from
a liquid hand gel to alcohol-based hand rub (Spiragel; Spiral),
to increase sanitizer coverage; (3) an increase in infection
control personnel; and the resulting (4) increased patient surveillance, in which every ward was visited on a daily basis
and every patient with undiagnosed diarrhea was surveyed.
For each patient with diarrhea, a surveillance form was filled
out by the infection control staff, with a detailed medical
history and information about prior diarrheal episodes, antibiotics and/or stool looseners received, and prior CDAD.
All patients with diarrhea had stool samples routinely
screened for Salmonella, Shigella, and Campylobacter species,
as well as Escherichia coli serotype 0157, C. difficile, and norovirus. New equipment was purchased; this included new
commodes that could be easily cleaned and bedpans that fit
both the commodes and the standard bedpan washers. In
addition, bedpan washers were monitored to ensure that the
correct washing temperature was consistently reached.

FLUOROQUINOLONE-RES1STANT, TOXIN A-NEGATIVE, TOXIN B-POSITIVE C. DIFFICILE

During the outbreak in 2003, several additional infection
control measures were included, along with heightened enforcement and awareness of existing measures. Efforts were
increased for the early identification and isolation of patients
with CDAD. During the outbreak period, a container of alcohol-based hand rub was placed at the end of the bed of
every patient with diarrhea. Healthcare workers with minor
contact with patients and clinically clean hands (according
to World Healthcare Organization guidelines) used alcoholbased hand rub to clean their hands between caring for different patients. When extensive patient contact had occurred,
HCWs were encouraged to wash their hands with soap and
water. A multifaceted education program was introduced, and
a major emphasis was placed on education and awareness of
this new hand-hygiene policy throughout the hospital. This
included a hand-hygiene campaign that targeted existing staff,
new staff, and patients. Lectures on hygiene were given by
infection control staff and consultants at grand rounds, staffinduction meetings, and meetings of the infection control
committee. Regular random checks with the ultraviolet test
for adequate hand hygiene were performed on staff throughout the hospital. Enhanced measures to control the environmental transmission of C. difficile were also introduced. These
included increasing the frequency of environmental cleaning
from once to twice daily with use of the standard chlorinereleasing disinfectant (1,000 ppm); enhanced cleaning of patient furniture, in which armchairs were cleaned as part of
daily cleaning procedure; and enhanced cleaning of shared
equipment, such as sphygmomanometer cuffs for measuring
blood pressure. Use of shared equipment was restricted to
similarly affected patients if used by a patient with diarrhea.

2001

2002

937

Molecular Analysis of C. difficile Isolates
Ninety C. difficile isolates were cultured from 64 of the 73
patients in this study. Sixty patients were infected with toxin
A-negative, toxin B-positive C. difficile isolates, whereas 4
patients were infected with toxin A-positive, toxin B-positive
C. difficile isolates. All sample isolates were positive for C.
difficile toxin B by use of the tissue-culture cytoxicity assay
(data not shown). Eighty-five (95%) of the isolates induced
a differential cytopathic effect, with complete rounding of the
fibroblast body in comparison with wild-type cytopathic effect, in which protrusions remain attached to the cell body.16
None of these isolates produced detectable toxin A (data not
shown). Toxinotyping identified a 1.7-kb deletion located in
the repeating domain of the tcdA gene in these isolates. PCR
identified RFLPs in the A3, Bl, and B3 domains, and isolates
were designated toxinotype VIII, in accordance with the
scheme of Rupnik et al.14 The 5 remaining isolates carried
the entire tcdA and tcdB genes, corresponding to toxinotype
0. All 90 isolates were analyzed by 16S-23S PCR ribotyping,
producing DNA banding patterns consisting of 10-14 bands,
with a size range of approximately 100-1,000 bp. One major
cluster of 85 toxin A-negative, toxin B-positive C. difficile
isolates was identified on the basis of a quantitative analysis
of the banding patterns obtained, and all isolates demonstrated banding patterns indistinguishable from strain type
1470 and PCR ribotype 017 (data not shown).
Antibiotic Susceptibility Testing
The MICs for the 90 C. difficile isolates from this study are
shown in Table 3. All isolates negative for toxin A and positive
for toxin B demonstrated a high level of resistance to the 5

2003

2004

2005

2. Fluoroquinolone and cephalosporin usage at Mater Misericordiae University Hospital, 2001-2005. Total use of fluoroquinolones (open triangles) and cephalosporins (black triangles) is overlaid as a line graph.

FIGURE
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fluoroquinolones tested, with MICs of greater than 32 fig/
mL. Resistance to clindamycin, erythromycin, and clarithromycin was also identified, with MICs of greater than 256
jiig/mL. In contrast, the MICs of the unrelated isolates positive
for toxins A and B were markedly reduced for levofloxacin,
moxifloxacin, and gatifloxacin, with median MICs of 3, 0.3,
and 0.2 pig/mL, respectively. Likewise, these isolates positive
for toxins A and B were up to 9-fold more susceptible to
clindamycin, erythromycin, and clarithromycin, with median
MICs of 4, 1.5, and 0.5 jug/mL, respectively.
DISCUSSION

We experienced a significant increase in the incidence of
CDAD at our institution over a 6-month period in 2003;
there were 73 patients diagnosed with CDAD, at least 14%
of whom had evidence of colitis. During this period, we saw
the emergence of a toxin-variant clone (negative for toxin A
and positive for toxin B) that was resistant to fluoroquinolones and macrolide, lincosamide, and streptogramin antibiotics. The trigger for the clonal expansion of this strain type
is not known, but we speculate that it may have been the
widespread use of fluoroquinolones and cephalosporins in
our institution in the preceding years, 2001 and 2002. Control
of this toxin-variant strain was achieved through infection
control measures other than curtailing the use of fluoroquinolones and cephalosporins. The hand-hygiene policy was
changed in 2002, when alcohol-based hand rub was introduced, and was not associated with an increase in the incidence of C. difficile infection, which is similar to findings
reported by Boyce et al.17 and Gordin et al.18 Although the
hand-hygiene policy was not altered with regard to the use
of alcohol hand rub, heightened awareness and enforcement
of this policy is likely to have contributed to control of this
outbreak.
Toxin-variant (toxin A-negative and toxin B-positive) C.
difficile strains have been isolated in several countries worldwide. Prevalence rates vary from 0.2% to 37% of isolates.19"22
Although several sporadic cases of CDAD due to toxinvariant strains have been reported, only 2 hospitals have
previously documented outbreaks of infection with this strain
type. Al-Barrak et al.23 were the first to report an outbreak
of infection with a toxin-variant strain of C. difficile, in Canada in 1998, in which 14 cases of toxin-variant CDAD were
diagnosed. In that study, 5 (36%) of the patients had recurrent
diarrhea, whereas 3 (20%) had severe colitis, associated with
a 66% mortality rate. Kuijper et al.24 described an outbreak
in The Netherlands in which 24 patients received a diagnosis
of toxin-variant CDAD. Three patients (13%) had recurrent
disease, and there were 7 patients with severe disease, with 1
death (14%). The rate of recurrence of CDAD noted in our
study (36%) and in other outbreaks due to toxin-variant
strains are similar to recurrence rates reported by us and others
for disease caused by isolates positive for toxins A and B.2
The rate of severe disease documented in our study is

higher than that reported elsewhere for nonvariant C. difficile.
In an earlier prospective study of patients who acquired toxin
A-positive, toxin B-positive C. difficile in Boston, we found
that less than 5% developed severe pseudomembranous colitis.2 Because 95% of the isolates we found were toxin variant,
we were unable to compare disease severity rates associated
with variant and nonvariant strains in our hospital. The prospective nature of our investigation into this outbreak did
allow us to assess each patient closely for symptoms of severe
disease. We used criteria for disease severity similar to those
used by McEllistrem et al.11 in a recent investigation of a
hospital outbreak of CDAD. In that study, the rate of severe
disease was 16.3%, which is similar to the rate in our study
(14%)." It is possible that we underestimated the rate of
severe disease because the decision to investigate patients by
use of CT was determined by the physician responsible for
the healthcare provision to those patients and was generally
reserved for sicker patients. We feel that it is unlikely that we
overestimated the rate of severe disease, because in addition
to having CT evidence of colitis, all patients classified as having severe disease had markedly elevated WBC counts, elevated temperatures, and abdominal pain or distension.
We found that patients who developed more-severe disease
had fewer comorbidities than did patients who developed
less-severe disease. However, the former were sicker patients;
50% of them were cared for in the ICU, and 80% of them
received nasogastric feeding. Although nasogastric feeding
was significantly associated with more-severe disease on univariate analysis, this was a marker for severe underlying disease, since the association lost significance once we controlled
for age and ICU stay. A limitation of our study was that
patients were studied after their diagnosis of CDAD was confirmed by laboratory testing. Consequently we were unable
to assess the severity of underlying diagnosis before the onset
of symptoms. We showed, in a previous study, that severity
of underlying disease is a strong independent risk factor for
CDAD.12 It is also likely to be a risk factor for severity of
CDAD.
C. difficile is not cultured routinely in microbiology laboratories in Ireland; therefore, we have little historic information with regard to the molecular epidemiology of C. difficile strains at our facility and at other Irish hospitals. This
limitation means that we cannot predict when this strain type
was introduced to our hospital or when it increased in frequency. Limited historical strain typing from outbreaks of
CDAD indicate that the earliest documentation of a PCRtype
017 isolate in Ireland was in 1996, and the first record of this
strain type at our hospital was in July 2001 (when 3 of 8
samples were PCR type 017). Although our evidence is limited
and is based on very small random-sample sizes, it does suggest that this strain increased in frequency between 2001 and
2003. After the present investigation, we identified this strain
type in a number of other Irish hospitals.25'26 Unfortunately,
C. difficile-positive status is shown only in a patient's medical
record at a given healthcare facility, and this information is
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not transmitted routinely when patients are transferred between facilities. This lack of epidemiological data makes it
impossible to trace the emergence of this C. difficile clone
throughout the greater Dublin area.
Prior antibiotic use is an important individual risk factor
for CDAD. Fluoroquinolone use has recently emerged as a
predominant risk factor in epidemics in Pittsburgh, Pennsylvania, and Quebec, Canada.5,9 In April 2003, before the
observed increase in CDAD, the antibiotic formulary had
changed such that ofloxacin and benzyl penicillin were recommended as first-line agents for the treatment of CAP. Before this, in 2001 and the first 5 months of 2002, levofloxacin
was used extensively in our hospital to treat CAP. This was
switched to cefuroxime and clarithromycin in May 2002. The
overall use of fluoroquinolones was halved in 2002 and did
not alter significantly between 2002 and 2005. However, we
speculate that use of levofloxacin, which accounted for almost
half of the total use of fluoroquinolones in 2001 and 2002,
may have promoted the acquisition of fluoroquinolone resistance by C. difficile, leading to the emergence of this variant
strain. Fluoroquinolone use continued in our hospital throughout the outbreak, and despite this, the incidence of CDAD
declined. However, the fluoroquinolones used were predominantly older classes (eg, ofloxacin and ciprofloxacin) with
lower antianaerobic activity than that of the newer classes of
fluoroquinolones recently associated with increased risk of
CDAD (levofloxcin and gatifloxacin).5'8'9 Although fluoroquinolones may have contributed to the emergence of this
variant strain, we achieved control of this variant strain
through much greater attention to infection control interventions, rather than through a change in the antibiotic use
policy.
Ongoing surveillance at our hospital indicates the persistence of this toxin A-negative, toxin B-positive C. difficile
strain, even though the incidence rate remains low. Recently,
investigators have determined that greater sporulation capacity,
along with increased antimicrobial resistance, may contribute
to the persistence of certain nosocomial C. difficile isolates;
however, the mechanisms by which the toxin A-negative, toxin
B-positive strain persists have not yet been examined. The
increased resistance to macrolide, lincosamide, and streptogramin antibiotics as well as fluoroquinolones seen among
the isolates in our outbreak is likely to contribute to their
persistence in both the hospital environment and the human
gut. Isolates from the 2 previously documented outbreaks of
CDAD due to toxin A-negative, toxin B-positive strains do
not appear to have been tested for fluoroquinolone resistance.
However, as in the outbreak at our hospital, isolates from the
outbreak in The Netherlands had an erm B gene that coded
for clindamycin resistance.24 Surveillance after the outbreak
in The Netherlands demonstrated that the toxin A-negative,
toxin B-positive isolates did not persist, and those toxin Anegative, toxin B-positive strains are no longer found at that
institution (E. Kuijper, oral communication).
In summary, we found that a C. difficile strain negative for
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toxin A and positive for toxin B and resistant to fluoroquinolones and macrolide, lincosamide, and streptogramin antibiotics is prevalent at our institution. Studies that address the
molecular epidemiology and antibiotic susceptibility of C.
difficile strains will help increase our understanding of the
factors that lead to institutional outbreaks. The virulence factors associated with epidemic strain types must be precisely
defined if the incidence of CDAD is to decline substantially.
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